S048 What’s Hot in Autoimmune Connective Tissue Disease
DESCRIPTION
Using clinical cases, classic and atypical presentations of cutaneous manifestations of autoimmune connective tissue diseases will be emphasized. This session will offer practical tips for diagnosis, appropriate evaluation, and advanced therapeutic management of patients with connective tissue diseases affecting the skin. Audience self-assessment will be encouraged through image review, and a case-based approach will be utilized to highlight relevance for the dermatology trainee or experienced clinician. Cases discussed will include those focusing on dermatomyositis, cutaneous lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, and morphea, amongst others.
LEARNING OBJECTIVES
Identify and diagnose classic and atypical presentations of cutaneous manifestations of autoimmune connective tissue diseases.
Select management options for skin involvement in complex connective tissue diseases based on the best available evidence from the literature.
SCHEDULE
1:00 PM
What's Hot in Autoimmune Connective Tissue Disease
DIRECTOR
Ruth Ann Vleugels, MD, MBA, MPH, FAAD
Mass General Brigham
SPEAKERS
Rochelle Castillo, MD, MS
Mass General Brigham
Janis Chang, MD
Brigham and Women's Hospital
Gabriela Andrea Cobos, MD, FAAD
Tufts Medical Center
Yoo Jung Kim, MD, FAAD
Avery H. LaChance, MPH, MD, FAAD
Mass General Brigham Dermatology
Francois Lagace, MD
Brigham and Women's Hospital
Christina Lam, MD, FAAD
Sarah Lonowski, MD, MBA, FAAD
Daniel Mazori, MD, FAAD
Michelle Min, MD, MSc, FAAD
Joshua Prenner, MD
Kathryn Rentfro, MD
Neda Shahriari, MD, FAAD
Leila Shayegan, MD, FAAD
DISCLOSURES
Rochelle Castillo, MD, MS
Johnson & Johnson Innovative Medicine – Advisory Board(Honoraria); Priovant Therapeutics – Consultant (1099 relationship)(Fees);
Janis Chang, MD
No financial relationships exist with ineligible companies.
Gabriela Andrea Cobos, MD, FAAD
AbbVie – Speaker(Fees); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Biogen – Investigator(Honoraria); Bristol Myers Squibb – Speaker/Faculty Education(Fees); Bristol-Myers Squibb – Advisory Board(Honoraria); Dermira/Lilly – Advisory Board(Honoraria), Speaker/Faculty Education(Fees); Incyte – Advisory Board(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Speaker(Fees); Octapharma – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Advisory Board(Fees); Sanofi/Regeneron – Advisory Board(Honoraria), Speaker(Fees); UCB – Advisory Board(Honoraria);
Yoo Jung Kim, MD, FAAD
No financial relationships exist with ineligible companies.
Avery H. LaChance, MPH, MD, FAAD
atheneum – Consultant (1099 relationship)(Fees); Biogen – Advisory Board(Fees); Guidepoint Global, LLC – Consultant (1099 relationship)(Fees); Johnson & Johnson Consumer, Inc. – Advisory Board(Honoraria); MEDACorp – Consultant (1099 relationship)(Fees); Merck – Investigator(Grants/Research Funding); Pfizer Inc. – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Priovant Therapeutics – Advisory Board(Fees); TD Cowen – Speaker(Honoraria);
Francois Lagace, MD
No financial relationships exist with ineligible companies.
Christina Lam, MD, FAAD
Biogen – Consultant (1099 relationship)(Fees), Investigator(Fees); Priovant Therapeutics – Advisory Board(Fees);
Sarah Lonowski, MD, MBA, FAAD
AstraZeneca – Investigator(Grants/Research Funding); Bristol Myers Squibb – Other(Other Financial Benefit); Eli Lilly – Investigator(Grants/Research Funding); Priovant Therapeutics – Advisory Board(No Compensation Received); Veradermics – Consultant (1099 relationship)(Fees);
Daniel Mazori, MD, FAAD
Veradermics – Advisory Board(Fees);
Michelle Min, MD, MSc, FAAD
Amgen – Investigator(Grants/Research Funding); AstraZeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Investigator(Grants/Research Funding); Bristol Myers Squibb – Advisory Board(Other Financial Benefit), Investigator(Grants/Research Funding); McGraw-Hill Companies – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Investigator(Grants/Research Funding);
Joshua Prenner, MD
No financial relationships exist with ineligible companies.
Kathryn Rentfro, MD
No financial relationships exist with ineligible companies.
Neda Shahriari, MD, FAAD
AbbVie – Consultant (1099 relationship)(Honoraria); AstraZeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Incyte – Consultant (1099 relationship)(Honoraria); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Investigator(Grants/Research Funding); UCB – Consultant (1099 relationship)(Honoraria);
Leila Shayegan, MD, FAAD
Priovant Therapeutics – Consultant (1099 relationship)(Fees);
Ruth Ann Vleugels, MD, MBA, MPH, FAAD
AbbVie – Consultant (1099 relationship)(Honoraria); Apogee Therapeutics – Consultant (1099 relationship)(Honoraria); Astra Zeneca – Consultant (1099 relationship)(Honoraria); BMS – Consultant (1099 relationship)(Honoraria); Eli Lilly – Consultant (1099 relationship)(Honoraria); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria);